acridin-9-yl-[4-(3-methoxy-phenyl)-piperazin-1-yl]-methanone | 1214741-69-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: acridin-9-yl-[4-(3-methoxy-phenyl)-piperazin-1-yl]-methanone
• 英文别名: Mrh9DH8znr；acridin-9-yl-[4-(3-methoxyphenyl)piperazin-1-yl]methanone
• CAS: 1214741-69-1
• 化学式: C₂₅H₂₃N₃O₂
• 分子量: 397.477
• InChiKey: YTECZQLINBWBIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  45.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  9-吖啶羧酸 、 1-(3-甲氧基苯基)哌嗪 在 N-cyclohexylcarbodiimide bound to N'-methyl polystyrene HL 作用下， 以 二氯甲烷 为溶剂， 反应 16.5h， 以56%的产率得到acridin-9-yl-[4-(3-methoxy-phenyl)-piperazin-1-yl]-methanone
  参考文献：
  名称：

  新型芳基和杂芳基酮哌嗪的重点库的设计和合成

  摘要：

  1-苯基-4-哌嗪基-羰基-取代的含氮杂环是在Zentaris发现的一类新的强效合成小分子微管蛋白抑制剂，具有很强的抗增殖活性。此类的先导结构 D-24203 被证明是包括乳腺癌和肾癌在内的不同异种移植模型中体内肿瘤生长的有效抑制剂。作为我们在先导优化过程中努力扩大结构多样性以及优化生物利用度参数（例如这些化合物的溶解度和代谢稳定性）的一部分，我们制作并评估了一个包含 320 种化合物的重点库。可以鉴定在细胞毒性和微管蛋白聚合测定中具有可比活性特性的五种新杂环化合物类别。

  DOI：

  10.1002/ardp.200400623

文献信息

• Predictive baseline biomarkers for use of vascular disrupting agents
  申请人：BIONOMICS LIMITED

  公开号：US10520508B2

  公开（公告）日：2019-12-31

  The present disclosure relates to the biological markers Ferritin and IL-8 that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.

  本公开涉及可预测患者对血管破坏剂治疗反应的生物标志物铁蛋白和IL-8。特别是，本公开涉及可预测癌症患者对血管破坏剂治疗反应的生物标记物，以及用血管破坏剂治疗癌症患者的方法。
• Predictive biomarkers
  申请人：BIONOMICS LIMITED

  公开号：US10564162B2

  公开（公告）日：2020-02-18

  The present disclosure relates to the biological markers SAP, SHBG, Myoglobin, MMP-9, and SCF that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.

  本公开涉及可预测患者对血管破坏剂治疗反应的生物标志物SAP、SHBG、肌红蛋白、MMP-9和SCF。特别是，本公开涉及可预测癌症患者对血管破坏剂治疗反应的生物标记物，以及用血管破坏剂治疗癌症患者的方法。
• PREDICTING RESPONSE TO CANCER THERAPY
  申请人：BIONOMICS LIMITED

  公开号：US20170135980A1

  公开（公告）日：2017-05-18

  The present invention relates to cancer markers that are predictive for cancer patent response to treatment with an m TOR inhibitor and a vascular disrupting agent. The present invention further relates to methods of treating a cancer patient subpopulation with a combination of an m TOR inhibitor and a vascular disrupting agent.
• PHARMACEUTICAL COMBINATION AND USES THEREOF
  申请人：BIONOMICS LIMITED

  公开号：US20180161302A1

  公开（公告）日：2018-06-14

  The invention relates to pharmaceutical combinations comprising a vascular disrupting agent, in particular the tubulin polymerisation inhibitor BNC105, and an immunotherapeutic agent, in particular an anti-PD-L1, PD-1 or CTLA-4 antibody, and use thereof in the treatment of cancer.
• PREDICTIVE BIOMARKERS
  申请人：BIONOMICS LIMITED

  公开号：US20180196048A1

  公开（公告）日：2018-07-12

  The present disclosure relates to the biological markers SAP, SHBG, Myoglobin, MMP-9, and SCF that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.